BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%

MT Newswires Live2025-09-18

BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.

The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.

The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.

BCAL Diagnostics shares rose 6% in morning trade on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2568441729?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568441729","market":"sg","top_or_hot":-1,"title":"BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, according to a Thursday filing with the Australian bourse.</p><p>The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.</p><p>The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.</p><p>BCAL Diagnostics shares rose 6% in morning trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-18 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, according to a Thursday filing with the Australian bourse.</p><p>The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.</p><p>The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.</p><p>BCAL Diagnostics shares rose 6% in morning trade on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDX.AU","symbol_name":"BCAL DIAGNOSTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568441729","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568441729","pubTimestamp":1758160198,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BCAL Diagnostics  partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.BCAL Diagnostics shares rose 6% in morning trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDX.AU":"BCAL DIAGNOSTICS LTD","XKO.AU":"标普/澳交所 300指数","BCAL":"Bank of Southern California NA","XAO.AU":"标普/澳交所 普通股指数","BK7067":"生物科技","XJO.AU":"标普/澳交所 200指数","BK4211":"区域性银行"},"translate_title":"BCAL Diagnostics与美国诊断公司合作；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":0.82,"XAO.AU":0.82,"BDX.AU":1,"BCAL":1.5,"XKO.AU":0.82},"content_text":"BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.BCAL Diagnostics shares rose 6% in morning trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2568441729","isCrawlerRequest":true}